Jeanette M.  Bjorkquist net worth and biography

Jeanette Bjorkquist Biography and Net Worth

Jeanette Bjorkquist is the Insider of Assembly Biosciences. They are 39 years old.

What is Jeanette M. Bjorkquist's net worth?

The estimated net worth of Jeanette M. Bjorkquist is at least $395.35 thousand as of November 2nd, 2026. Bjorkquist owns 17,673 shares of Assembly Biosciences stock worth more than $395,345 as of November 12th. This net worth approximation does not reflect any other investments that Bjorkquist may own. Learn More about Jeanette M. Bjorkquist's net worth.

How do I contact Jeanette M. Bjorkquist?

The corporate mailing address for Bjorkquist and other Assembly Biosciences executives is Two Tower Place, 7th Floor, South San Francisco, CA, 94080. Assembly Biosciences can also be reached via phone at (833) 509-4583 and via email at [email protected]. Learn More on Jeanette M. Bjorkquist's contact information.

Has Jeanette M. Bjorkquist been buying or selling shares of Assembly Biosciences?

Within the last three months, Jeanette M. Bjorkquist has sold $14,263.74 in Assembly Biosciences stock. Most recently, Jeanette M. Bjorkquist sold 727 shares of the business's stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $19.62, for a transaction totalling $14,263.74. Following the completion of the sale, the insider now directly owns 17,673 shares of the company's stock, valued at $346,744.26. Learn More on Jeanette M. Bjorkquist's trading history.

Who are Assembly Biosciences' active insiders?

Assembly Biosciences' insider roster includes Jeanette Bjorkquist (Insider), William Delaney (Insider), Michael Houghton (Director), John McHutchison (CEO), Jason Okazaki (CEO), Timothy Springer (Director), and Nicole White (Insider). Learn More on Assembly Biosciences' active insiders.

Are insiders buying or selling shares of Assembly Biosciences?

During the last twelve months, insiders at the biopharmaceutical company sold shares 5 times. They sold a total of 12,144 shares worth more than $238,370.55. The most recent insider tranaction occured on November, 2nd when insider Jeanette M Bjorkquist sold 727 shares worth more than $14,263.74. Insiders at Assembly Biosciences own 3.5% of the company. Learn More about insider trades at Assembly Biosciences.

Information on this page was last updated on 11/2/2026.

Jeanette M. Bjorkquist Insider Trading History at Assembly Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/2/2026Sell727$19.62$14,263.7417,673View SEC Filing Icon  
6/17/2026Sell29$23.25$674.2514,560View SEC Filing Icon  
3/31/2025Sell180$9.85$1,773.004,617View SEC Filing Icon  
5/23/2024Sell24$14.93$358.323,142View SEC Filing Icon  
4/1/2024Sell114$13.07$1,489.983,166View SEC Filing Icon  
7/24/2023Sell70$12.84$898.802,224View SEC Filing Icon  
5/23/2023Sell22$12.48$274.562,294View SEC Filing Icon  
3/30/2023Sell64$9.84$629.761,983View SEC Filing Icon  
See Full Table

Jeanette M. Bjorkquist Buying and Selling Activity at Assembly Biosciences

This chart shows Jeanette M. Bjorkquist's buying and selling at Assembly Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Assembly Biosciences Company Overview

Assembly Biosciences logo
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $20.70
Low: $20.56
High: $22.15

50 Day Range

MA: $23.88
Low: $19.51
High: $36.72

2 Week Range

Now: $20.70
Low: $19.20
High: $39.71

Volume

127,589 shs

Average Volume

193,838 shs

Market Capitalization

$421.47 million

P/E Ratio

20.32

Dividend Yield

N/A

Beta

1.26